article · Clinical and Translational Science
Circulating serum biomarkers have prognostic value in patients with advanced NSCLC, yet their potential still remains underappreciated at present. This review discusses classical approaches of biomarker data analysis, highlighting gaps, and summarizing current methodologies to evaluate the relationship between serum biomarkers and clinical outcome in advanced NSCLC. Showcased for serum biomarker data exploitation of a phase III study in advanced NSCLC patients, this review also promotes and offers perspectives on how to analyze and interpret longitudinal biomarker data using pharmacometric approaches for potential implementation into clinical practice.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1111/cts.70494
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
